Lauren Pignataro Rakitin specializes in transactional matters in the life sciences industry, with a particular focus on complex strategic collaborations and licensing arrangements. Lauren advises…
Lauren Pignataro Rakitin specializes in transactional matters in the life sciences industry, with a particular focus on complex strategic collaborations and licensing arrangements. Lauren advises a broad range of clients, from start-up and biotech companies to global pharmaceutical companies. By focusing exclusively in the life sciences industry, Lauren has established a deep understanding of the complex needs of pharmaceutical and biotechnology companies as they navigate the life cycle of their products, from discovery and development to commercialization and generic/biosimilar entry.
Lauren routinely advises on:
strategic licensing and collaboration agreements for the discovery, development and/or commercialization of life sciences products;
in-licensing of foundational IP and out-licensing of IP that is no longer core to the portfolio to unlock further value; and
commercial agreements, including CRO, clinical trial, manufacturing, co-promotion and distribution agreements.
Lauren Pignataro Rakitin specializes in transactional matters in the life sciences industry, with a particular focus on complex strategic collaborations and licensing arrangements. Lauren advises…
Lauren Pignataro Rakitin specializes in transactional matters in the life sciences industry, with a particular focus on complex strategic collaborations and licensing arrangements. Lauren advises a broad range of clients, from start-up and biotech companies to global pharmaceutical companies. By focusing exclusively in the life sciences industry, Lauren has established a deep understanding of the complex needs of pharmaceutical and biotechnology companies as they navigate the life cycle of their products, from discovery and development to commercialization and generic/biosimilar entry.
Lauren routinely advises on:
strategic licensing and collaboration agreements for the discovery, development and/or commercialization of life sciences products;
in-licensing of foundational IP and out-licensing of IP that is no longer core to the portfolio to unlock further value; and
commercial agreements, including CRO, clinical trial, manufacturing, co-promotion and distribution agreements.